Efficacy and tolerance of enzymatic hydrolysed collagen (EHC) vs. glucosamine sulphate (GS) in the treatment of knee osteoarthritis (KOA)

This was a 13-week, multicentre, randomised, parallel, double-blind study. One hundred men and women volunteers aged ≥40 years with knee osteoarthritis (KOA) were randomised to once daily enzymatic hydrolysed collagen (EHC) 10 g or glucosamine sulphate (GS) 1.5 g for 90 consecutive days. Follow-up t...

Full description

Saved in:
Bibliographic Details
Published in:International orthopaedics 2011-03, Vol.35 (3), p.341-348
Main Authors: Trc, Tomas, Bohmova, Jana
Format: Article
Language:English
Subjects:
Activities of Daily Living
Adult
Collagen
Collagen - metabolism
Collagen - therapeutic use
Collagenases - metabolism
Double-Blind Method
Female
Glucosamine
Glucosamine - therapeutic use
Health Status
Humans
Hydrolysis
Ibuprofen
Inventories
Joints
Knee
Knee Joint - drug effects
Knee Joint - physiopathology
Male
Medicine
Medicine & Public Health
Original Paper
Orthopedics
Osteoarthritis
Osteoarthritis, Knee - drug therapy
Osteoarthritis, Knee - physiopathology
Pain
Pain - drug therapy
Pain - physiopathology
Quality of Life
Severity of Illness Index
Surveys and Questionnaires
Tablets
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This was a 13-week, multicentre, randomised, parallel, double-blind study. One hundred men and women volunteers aged ≥40 years with knee osteoarthritis (KOA) were randomised to once daily enzymatic hydrolysed collagen (EHC) 10 g or glucosamine sulphate (GS) 1.5 g for 90 consecutive days. Follow-up took place after two weeks and after one, two and three months. Primary [visual analogue scale (VAS), Western Ontario and McMaster Universities (WOMAC Index)] and secondary outcomes variables, assessed at weeks two, four, eight and 12, were KOA pain intensity measured by quadruple visual analogue scales in the target knee, the WOMAC total score index, patient’s and investigator’s global assessments of disease activity, joint assessment, use of rescue medication (ibuprofen 400 mg tablets) and assessment of Quality of Life index (SF-36 Questionnaire). Safety and tolerability were also evaluated. Clear improvement was observed in both joint pain and symptoms in patients with KOA treated with EHC (Colatech®) and significant differences were observed. Mean reductions from baseline for EHC 10 g daily and GS 1.5 g, respectively, were KOA pain intensity reduction in the target knee for Colatech® ( p  
ISSN:0341-2695
1432-5195
DOI:10.1007/s00264-010-1010-z